An Open-Label Study to Evaluate the Prevalence of Phenotypic Poor Metabolizers at CYP2D6 Among Venlafaxine-Treated Outpatients With Depression.
Phase of Trial: Phase IV
Latest Information Update: 05 Jan 2011
At a glance
- Drugs Venlafaxine (Primary)
- Indications Depressive disorders
- Focus Pharmacogenomic; Pharmacokinetics
- Sponsors Wyeth
- 21 May 2010 Actual patient number changed from 966 to 971 added as reported by ClinicalTrials.gov.
- 07 Aug 2009 Actual number of patients (966) added as reported by ClinicalTrials.gov.
- 07 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.